Lenvatinib Administration for Anaplastic Thyroid Carcinoma with Brain Metastasis
We describe the use of the tyrosine kinase inhibitor lenvatinib in a patient with brain tumor metastases from anaplastic thyroid carcinoma (ATC). A 52-year-old Japanese male presented with consciousness loss. Imaging revealed a thyroid tumor and multiple brain lesions. After the brain tumor's r...
Gespeichert in:
| Veröffentlicht in: | Acta medica Okayama 2023-04, Vol.77 (2), p.227 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 2 |
| container_start_page | 227 |
| container_title | Acta medica Okayama |
| container_volume | 77 |
| creator | Obayashi, Atsuto Aoki, Kazuma Wada, Tadayoshi Furuie, Hiromi Kuraoka, Kazuya Hamamoto, Takao Tatsukawa, Takaharu |
| description | We describe the use of the tyrosine kinase inhibitor lenvatinib in a patient with brain tumor metastases from anaplastic thyroid carcinoma (ATC). A 52-year-old Japanese male presented with consciousness loss. Imaging revealed a thyroid tumor and multiple brain lesions. After the brain tumor's resection, pathology results provided the diagnosis of ATC. Total thyroidectomy was performed, followed by whole-brain irradiation. Additional brain lesions later developed, and lenvatinib therapy was initiated with no remarkable complications. However, the treatment effects were limited, and the patient died 2 months after starting lenvatinib, 202 days after the initial brain surgery. Relevant literature is discussed. |
| doi_str_mv | 10.18926/AMO/65155 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_37094963</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>37094963</sourcerecordid><originalsourceid>FETCH-LOGICAL-j312t-29df711eb9ff4da18ac0db898ce906db67d66ecfc839a8f5a355fb04e82ebd793</originalsourceid><addsrcrecordid>eNo1j8tKAzEYhbNQbK1ufADJC4xNJpNMshyLVmFKXVRwV_7caErnQhKVvr0D6uo7Bz4OHITuKHmgUpVi2Wy2S8Ep5xdoTpgUBSPkY4auUzoSUlZKkCs0YzVRU2Rz9Na6_gty6IPGje0mphynPvTYDxE3PYwnSDkYvDuc4xAsXkE0oR86wN8hH_BjhNDjjcuTBSmkG3Tp4ZTc7R8X6P35abd6Kdrt-nXVtMWR0TIXpbK-ptRp5X1lgUowxGqppHGKCKtFbYVwxhvJFEjPgXHuNamcLJ22tWILdP-7O37qztn9GEMH8bz_v8Z-AIfaT9c</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Lenvatinib Administration for Anaplastic Thyroid Carcinoma with Brain Metastasis</title><source>MEDLINE</source><source>Freely Accessible Japanese Titles</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Obayashi, Atsuto ; Aoki, Kazuma ; Wada, Tadayoshi ; Furuie, Hiromi ; Kuraoka, Kazuya ; Hamamoto, Takao ; Tatsukawa, Takaharu</creator><creatorcontrib>Obayashi, Atsuto ; Aoki, Kazuma ; Wada, Tadayoshi ; Furuie, Hiromi ; Kuraoka, Kazuya ; Hamamoto, Takao ; Tatsukawa, Takaharu</creatorcontrib><description>We describe the use of the tyrosine kinase inhibitor lenvatinib in a patient with brain tumor metastases from anaplastic thyroid carcinoma (ATC). A 52-year-old Japanese male presented with consciousness loss. Imaging revealed a thyroid tumor and multiple brain lesions. After the brain tumor's resection, pathology results provided the diagnosis of ATC. Total thyroidectomy was performed, followed by whole-brain irradiation. Additional brain lesions later developed, and lenvatinib therapy was initiated with no remarkable complications. However, the treatment effects were limited, and the patient died 2 months after starting lenvatinib, 202 days after the initial brain surgery. Relevant literature is discussed.</description><identifier>ISSN: 0386-300X</identifier><identifier>DOI: 10.18926/AMO/65155</identifier><identifier>PMID: 37094963</identifier><language>eng</language><publisher>Japan</publisher><subject>Antineoplastic Agents - therapeutic use ; Brain Neoplasms ; Humans ; Male ; Middle Aged ; Thyroid Carcinoma, Anaplastic - drug therapy ; Thyroid Carcinoma, Anaplastic - pathology ; Thyroid Neoplasms</subject><ispartof>Acta medica Okayama, 2023-04, Vol.77 (2), p.227</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37094963$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Obayashi, Atsuto</creatorcontrib><creatorcontrib>Aoki, Kazuma</creatorcontrib><creatorcontrib>Wada, Tadayoshi</creatorcontrib><creatorcontrib>Furuie, Hiromi</creatorcontrib><creatorcontrib>Kuraoka, Kazuya</creatorcontrib><creatorcontrib>Hamamoto, Takao</creatorcontrib><creatorcontrib>Tatsukawa, Takaharu</creatorcontrib><title>Lenvatinib Administration for Anaplastic Thyroid Carcinoma with Brain Metastasis</title><title>Acta medica Okayama</title><addtitle>Acta Med Okayama</addtitle><description>We describe the use of the tyrosine kinase inhibitor lenvatinib in a patient with brain tumor metastases from anaplastic thyroid carcinoma (ATC). A 52-year-old Japanese male presented with consciousness loss. Imaging revealed a thyroid tumor and multiple brain lesions. After the brain tumor's resection, pathology results provided the diagnosis of ATC. Total thyroidectomy was performed, followed by whole-brain irradiation. Additional brain lesions later developed, and lenvatinib therapy was initiated with no remarkable complications. However, the treatment effects were limited, and the patient died 2 months after starting lenvatinib, 202 days after the initial brain surgery. Relevant literature is discussed.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Brain Neoplasms</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Thyroid Carcinoma, Anaplastic - drug therapy</subject><subject>Thyroid Carcinoma, Anaplastic - pathology</subject><subject>Thyroid Neoplasms</subject><issn>0386-300X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j8tKAzEYhbNQbK1ufADJC4xNJpNMshyLVmFKXVRwV_7caErnQhKVvr0D6uo7Bz4OHITuKHmgUpVi2Wy2S8Ep5xdoTpgUBSPkY4auUzoSUlZKkCs0YzVRU2Rz9Na6_gty6IPGje0mphynPvTYDxE3PYwnSDkYvDuc4xAsXkE0oR86wN8hH_BjhNDjjcuTBSmkG3Tp4ZTc7R8X6P35abd6Kdrt-nXVtMWR0TIXpbK-ptRp5X1lgUowxGqppHGKCKtFbYVwxhvJFEjPgXHuNamcLJ22tWILdP-7O37qztn9GEMH8bz_v8Z-AIfaT9c</recordid><startdate>20230401</startdate><enddate>20230401</enddate><creator>Obayashi, Atsuto</creator><creator>Aoki, Kazuma</creator><creator>Wada, Tadayoshi</creator><creator>Furuie, Hiromi</creator><creator>Kuraoka, Kazuya</creator><creator>Hamamoto, Takao</creator><creator>Tatsukawa, Takaharu</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20230401</creationdate><title>Lenvatinib Administration for Anaplastic Thyroid Carcinoma with Brain Metastasis</title><author>Obayashi, Atsuto ; Aoki, Kazuma ; Wada, Tadayoshi ; Furuie, Hiromi ; Kuraoka, Kazuya ; Hamamoto, Takao ; Tatsukawa, Takaharu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j312t-29df711eb9ff4da18ac0db898ce906db67d66ecfc839a8f5a355fb04e82ebd793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Brain Neoplasms</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Thyroid Carcinoma, Anaplastic - drug therapy</topic><topic>Thyroid Carcinoma, Anaplastic - pathology</topic><topic>Thyroid Neoplasms</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Obayashi, Atsuto</creatorcontrib><creatorcontrib>Aoki, Kazuma</creatorcontrib><creatorcontrib>Wada, Tadayoshi</creatorcontrib><creatorcontrib>Furuie, Hiromi</creatorcontrib><creatorcontrib>Kuraoka, Kazuya</creatorcontrib><creatorcontrib>Hamamoto, Takao</creatorcontrib><creatorcontrib>Tatsukawa, Takaharu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Acta medica Okayama</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Obayashi, Atsuto</au><au>Aoki, Kazuma</au><au>Wada, Tadayoshi</au><au>Furuie, Hiromi</au><au>Kuraoka, Kazuya</au><au>Hamamoto, Takao</au><au>Tatsukawa, Takaharu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lenvatinib Administration for Anaplastic Thyroid Carcinoma with Brain Metastasis</atitle><jtitle>Acta medica Okayama</jtitle><addtitle>Acta Med Okayama</addtitle><date>2023-04-01</date><risdate>2023</risdate><volume>77</volume><issue>2</issue><spage>227</spage><pages>227-</pages><issn>0386-300X</issn><abstract>We describe the use of the tyrosine kinase inhibitor lenvatinib in a patient with brain tumor metastases from anaplastic thyroid carcinoma (ATC). A 52-year-old Japanese male presented with consciousness loss. Imaging revealed a thyroid tumor and multiple brain lesions. After the brain tumor's resection, pathology results provided the diagnosis of ATC. Total thyroidectomy was performed, followed by whole-brain irradiation. Additional brain lesions later developed, and lenvatinib therapy was initiated with no remarkable complications. However, the treatment effects were limited, and the patient died 2 months after starting lenvatinib, 202 days after the initial brain surgery. Relevant literature is discussed.</abstract><cop>Japan</cop><pmid>37094963</pmid><doi>10.18926/AMO/65155</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0386-300X |
| ispartof | Acta medica Okayama, 2023-04, Vol.77 (2), p.227 |
| issn | 0386-300X |
| language | eng |
| recordid | cdi_pubmed_primary_37094963 |
| source | MEDLINE; Freely Accessible Japanese Titles; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Antineoplastic Agents - therapeutic use Brain Neoplasms Humans Male Middle Aged Thyroid Carcinoma, Anaplastic - drug therapy Thyroid Carcinoma, Anaplastic - pathology Thyroid Neoplasms |
| title | Lenvatinib Administration for Anaplastic Thyroid Carcinoma with Brain Metastasis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T13%3A48%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lenvatinib%20Administration%20for%20Anaplastic%20Thyroid%20Carcinoma%20with%20Brain%20Metastasis&rft.jtitle=Acta%20medica%20Okayama&rft.au=Obayashi,%20Atsuto&rft.date=2023-04-01&rft.volume=77&rft.issue=2&rft.spage=227&rft.pages=227-&rft.issn=0386-300X&rft_id=info:doi/10.18926/AMO/65155&rft_dat=%3Cpubmed%3E37094963%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/37094963&rfr_iscdi=true |